In patients with non-small cell lung cancer, the combined treatment anti-CTLA-4/anti-PD-1 was more efficient in patients with a higher TMB (≥10 mutations per megabase) compared to patients with a lower TMB [323]. Here, PDCD1 is linked to non-small cell lung carcinoma.